Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs ZJYL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZJYL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–3 Matrix Metrics)

ZJYL Overall Winner 6-Pillar Tally: EKSO 0 – 5 ZJYL (1 Tie) Matrix Metrics: EKSO 3 – 6 ZJYL

As of Nov 20, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ZJYL carries 40.7/100 (SELL) at $3.38 (N/M Forward P/E, 2.1% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ZJYL 40.7/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -119.7% operating margin) and revenue trajectory (-9.7% vs. -38.3% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs ZJYL
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
ZJYL NASDAQ Head-to-Head Winner
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$3.38
+1.2% 1D
Market Cap $531.7M
TTM Revenue $508M
Forward P/E N/M
Beta / 30D Vol 0.72β · 177% Vol
Unified Composite Score
40.7 / 100 SELL
Tech 22.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.4% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $3.11 · SMA50: $2.46

6-Pillar Scorecard Institutional Category Breakdown (EKSO 0 – 5 ZJYL)

Columns: Metric · EKSO · ZJYL
1. Valuation Multiples ZJYL
Forward P/E N/M N/M
Trailing P/E N/M 17.6x
PEG Ratio N/M N/M
EV / Revenue 3.3x 1.0x
2. Growth & Scale ZJYL
Revenue Growth (YoY) -38.3% -9.7%
Earnings Growth (YoY) +0.0% -32.0%
TTM Revenue (USD) $13M $508M
Market Cap $42.0M $531.7M
3. Profitability & Quality ZJYL
Gross Margin 53.5% 31.3%
Operating Margin -119.7% 2.1%
Net Profit Margin -91.4% 5.9%
Return on Equity (ROE) -107.6% 4.0%
4. Balance Sheet & Cash Flow ZJYL
Cash Generation (TTM) -$11M EBITDA $17M EBITDA
Cash Flow Margin -86.0% EBITDA Mgn 3.3% EBITDA Mgn
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $3.87 Book/Sh · 4.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZJYL
OpEx & R&D Intensity N/A 29.2% of Rev ($148M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (3) vs ZJYL (6)
Institutional Metric EKSO ZJYL Criterion Row Edge
Market Capitalization
Scale
$42.0M $531.7M Larger Scale ZJYL
Trailing P/E Ratio
Valuation
N/M 17.6x Lower Multiple ZJYL
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.3% -9.7% Higher Growth ZJYL
Operating Margin (TTM)
Profitability
-119.7% 2.1% Higher Margin ZJYL
Net Profit Margin
Profitability
-91.4% 5.9% Higher Margin ZJYL
Return on Equity (ROE)
Capital Efficiency
-107.6% 4.0% Higher ROE ZJYL
52-Week Range Position
Momentum
87% ($0–$14) 68% ($0–$5) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 0.72β · 177% Vol Lower Realized Risk EKSO
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 40.7 / 100 (SELL) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $508M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 31.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) $17M EBITDA ($3.87 Book/Sh · 4.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZJYL +9.6 pp
EKSO: +25.53% · ZJYL: +35.13%
3M Horizon ZJYL +1738.28 pp
EKSO: +25.93% · ZJYL: +1764.21%
6M Horizon ZJYL +643.26 pp
EKSO: +182.63% · ZJYL: +825.89%
1Y Horizon ZJYL +643.26 pp
EKSO: +182.63% · ZJYL: +825.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs ZJYL. Trailing 12-month operating profitability (EKSO -119.7% vs ZJYL 2.1%) and valuation multiples (EKSO N/M vs ZJYL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
ZJYL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$508M
Gross Margin31.3%
Op. Margin2.1%
ROE / Fwd P/E4.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZJYL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZJYL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZJYL Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $531.7M market capitalization and 2.1% operating margin.
OpEx & R&D Reinvestment 29.2% of Rev ($148M)
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs ZJYL Key Questions & Quantitative Answers

As of Nov 20, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas ZJYL carries 40.7/100 (SELL) at $3.38 (N/M Forward P/E, 2.1% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. ZJYL 40.7/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -119.7% operating margin) and revenue trajectory (-9.7% vs. -38.3% YoY).

ZJYL leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with ZJYL at -9.7% YoY revenue growth and -32.0% YoY earnings growth on $508M TTM revenue (31.3% gross margin, 2.1% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $508M for ZJYL. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 29.2% of Rev ($148M) (0 disclosures) for ZJYL.

ZJYL screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas ZJYL trades at N/M Forward P/E, 17.6x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (3.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus ZJYL (4.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, ZJYL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.72β · 177% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.